A Phase 1 Study Evaluating Safety, Tolerability, and Pharmacokinetics of Escalating Doses of ASP1235 (AGS62P1) Given as Monotherapy in Subjects with Acute Myeloid Leukemia (AML)
The goals of this clinical research study are to find the highest tolerable dose of ASP1235 (AGS62P1) that can be given to patients with acute myeloid leukemia (AML) that is relapsed (has come back) or is resistant to therapy and to learn if the highest tolerable dose of ASP1235 can help to control AML. The safety of ASP1235 will also be studied. This is the first study using ASP1235 (AGS62P1) in humans.
Treatment Location: N/A
IRB Review and Approval Date: 04/14/2017
Recruitment Status: Closed
Projected Accrual: N/A
Information and next steps
For general questions about clinical trials: